130 related articles for article (PubMed ID: 37565331)
1. HDAC6 detector: online application for evaluating compounds as potential histone deacetylase 6 inhibitors.
Tinkov OV; Grigorev VY; Grigoreva LD; Osipov VN; Kolotaev AV; Khachatryan DS
SAR QSAR Environ Res; 2023; 34(8):619-637. PubMed ID: 37565331
[TBL] [Abstract][Full Text] [Related]
2. QSAR analysis and experimental evaluation of new quinazoline-containing hydroxamic acids as histone deacetylase 6 inhibitors.
Tinkov OV; Grigorev VY; Grigoreva LD; Osipov VN; Kolotaev AV; Khachatryan DS
SAR QSAR Environ Res; 2022 Jul; 33(7):513-532. PubMed ID: 35786151
[TBL] [Abstract][Full Text] [Related]
3. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
4. HDAC1 PREDICTOR: a simple and transparent application for virtual screening of histone deacetylase 1 inhibitors.
Tinkov OV; Grigorev VY; Grigoreva LD; Osipov VN
SAR QSAR Environ Res; 2022 Dec; 33(12):915-931. PubMed ID: 36548122
[TBL] [Abstract][Full Text] [Related]
5. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
7. Binding of inhibitors to active-site mutants of CD1, the enigmatic catalytic domain of histone deacetylase 6.
Osko JD; Christianson DW
Acta Crystallogr F Struct Biol Commun; 2020 Sep; 76(Pt 9):428-437. PubMed ID: 32880591
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Wang XX; Wan RZ; Liu ZP
Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
[TBL] [Abstract][Full Text] [Related]
9. Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
Song H; Niu X; Quan J; Li Y; Yuan L; Wang J; Ma C; Ma E
Bioorg Chem; 2020 Apr; 97():103679. PubMed ID: 32120077
[TBL] [Abstract][Full Text] [Related]
10. Fragment-Based Drug Design of Selective HDAC6 Inhibitors.
Ruzic D; Djokovic N; Nikolic K
Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
[TBL] [Abstract][Full Text] [Related]
12. In silico design of HDAC6 inhibitors with neuroprotective effects.
Sixto-López Y; Gómez-Vidal JA; de Pedro N; Bello M; Rosales-Hernández MC; Correa-Basurto J
J Biomol Struct Dyn; 2022; 40(24):14204-14222. PubMed ID: 34784487
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
Yang J; Cheng G; Xu Q; Luan S; Wang S; Liu D; Zhao L
Bioorg Med Chem; 2018 May; 26(8):1418-1425. PubMed ID: 29500130
[TBL] [Abstract][Full Text] [Related]
14. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
Porter NJ; Mahendran A; Breslow R; Christianson DW
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
[TBL] [Abstract][Full Text] [Related]
15. Recent innovative advances in the discovery of selective HDAC6 inhibitors.
T Tavares M; Shen S
Future Med Chem; 2021 Jun; 13(12):1017-1019. PubMed ID: 33906379
[No Abstract] [Full Text] [Related]
16. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, Bioactivity Evaluation, Crystal Structures, and In Silico Studies of New α-Amino Amide Derivatives as Potential Histone Deacetylase 6 Inhibitors.
Xu Y; Tang H; Xu Y; Guo J; Zhao X; Meng Q; Xiao J
Molecules; 2022 May; 27(10):. PubMed ID: 35630812
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
[TBL] [Abstract][Full Text] [Related]
19. Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo.
Li Y; Quan J; Song H; Li D; Ma E; Wang Y; Ma C
Bioorg Chem; 2021 Sep; 114():105081. PubMed ID: 34153811
[TBL] [Abstract][Full Text] [Related]
20. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
